A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Lee, Soon Il | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Park, Silvia | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Lee, Sang-Cheol | - |
dc.contributor.author | Sun, Jong-Mu | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.date.available | 2020-02-28T02:45:47Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-02 | - |
dc.identifier.issn | 1558-7673 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8607 | - |
dc.description.abstract | The present multicenter phase II study evaluated the efficacy and safety of weekly docetaxel as second-line chemotherapy for metastatic urothelial carcinoma. Weekly docetaxel was well tolerated but demonstrated modest activity, with a response rate of 6%, a median progression-free survival (PFS) of 1.4 months, and a median overall survival (OS) of 8.3 months. The dichotomy between PFS and OS was likely associated with subsequent platinum-based chemotherapy received by 58% of the patients. Background: Docetaxel is commonly used for second-line therapy for metastatic urothelial carcinoma (UC). However, myelosuppression is a substantial concern when the traditional 3-week docetaxel cycle is used. The present multicenter phase II study evaluated the efficacy and safety of weekly docetaxel as second-line chemotherapy for metastatic UC. Patients and Methods: Patients with progression after previous platinum-based chemotherapy for advanced or metastatic disease were treated with docetaxel 30 mg/m(2) on days 1 and 8 every 21 days. The primary endpoint was the response rate. Results: The study enrolled 31 patients. Their median age was 64 years (range, 40-79 years). An Eastern Cooperative Oncology Group performance status of 1, liver metastasis, and a hemoglobin level < 10 g/dL were observed in 100%, 32%, and 23% of patients, respectively. Previous platinum-based chemotherapy had been administered for metastatic disease in 29 patients (94%). Although fatigue (13%) and anorexia (6%) were the most frequently observed grade 3 to 4 toxicities, the safety profiles were generally mild and manageable. Two patients (6%) achieved an objective response, which was maintained for 3.0 to 7.8 months. Eight patients experienced disease stabilization (disease control rate, 32%). The median progression-free survival (PFS) and overall survival (OS) were 1.4 months (95% confidence interval [CI], 1.3-1.6) and 8.3 months (95% CI, 5.9-10.6), respectively. A relatively long OS was associated with further salvage platinum-based chemotherapy (n = 18, 58%) showing an encouraging activity (response rate, 44%; median PFS, 4.0 months). Conclusion: Second-line chemotherapy with weekly docetaxel was well tolerated but demonstrated modest activity in patients with metastatic UC. A platinum-based combination as second-line treatment might be considered for selected patients. (C) 2016 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | CIG MEDIA GROUP, LP | - |
dc.relation.isPartOf | CLINICAL GENITOURINARY CANCER | - |
dc.subject | TRANSITIONAL-CELL CARCINOMA | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | WEEKLY PACLITAXEL | - |
dc.subject | LUNG-CANCER | - |
dc.subject | G-CSF | - |
dc.subject | M-VAC | - |
dc.subject | CISPLATIN | - |
dc.subject | PLUS | - |
dc.subject | MULTICENTER | - |
dc.subject | VINFLUNINE | - |
dc.title | A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000367380100036 | - |
dc.identifier.doi | 10.1016/j.clgc.2015.09.008 | - |
dc.identifier.bibliographicCitation | CLINICAL GENITOURINARY CANCER, v.14, no.1, pp.76 - 81 | - |
dc.identifier.scopusid | 2-s2.0-84952876659 | - |
dc.citation.endPage | 81 | - |
dc.citation.startPage | 76 | - |
dc.citation.title | CLINICAL GENITOURINARY CANCER | - |
dc.citation.volume | 14 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Bladder cancer | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Phase II | - |
dc.subject.keywordAuthor | Second-line | - |
dc.subject.keywordAuthor | Urothelial carcinoma | - |
dc.subject.keywordPlus | TRANSITIONAL-CELL CARCINOMA | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | WEEKLY PACLITAXEL | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | G-CSF | - |
dc.subject.keywordPlus | M-VAC | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | VINFLUNINE | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.